Acamprosate, also known by the popular brand name Campral, is a medication which is predominantly used in combination with counselling to treat alcohol dependence. It was originally developed by the pharmaceutical products manufacturer Lipha, a subsidiary of Merck KGaA, and was approved for marketing in Europe in 1989. In 2001 the drugs manufacturing company Forest Laboratories acquired the rights to produce the drug in the United States and was subsequently given FDA approval in 2004. Since the patent has expired and generic versions have entered the global marketplace at an array of price points, it has emerged cost-effective for acamprosate manufacturers and acamprosate suppliers to produce and sell to distributors. This has been further reinforced by studies conducted by Confluence Pharmaceuticals in 2015, into whether acamprosate could be a potential treatment for fragile X syndrome, with the research since having been granted orphan drug status by both the FDA and EMA.
Method of action of acamprosate:
Acamprosate is thought to function through the stabilisation of alcohol-induced disruption of the chemical balance in the brain. Possibly through blocking glutaminergic N-methyl-D-aspartate receptors while activating gamma-aminobutyric acid type A receptors. Interestingly, acamprosate used alone has a marginal effect on therapy usefulness. With combined therapy involving abstinence from alcohol alongside attendance to support groups and counselling instead needed to display marked improvement in most individuals.
Form and dosage of acamprosate:
Although the final form is dependent on both the acamprosate manufacturers and acamprosate suppliers wishes, acamprosate is typically found for sale and wholesale in tablet form. It is not a controlled substance and thus does not require a prescription to purchase, however, it is recommended for adults 18-65 years old and with bodyweight up to 60 kg to only take 666 mg once daily at breakfast followed by two doses of 333 mg, at midday and night. For adults over the weight of 60 kg, the recommended dose increases to 666 mg three times a day. Common side effects include abdominal pain, diarrhoea, flatulence, nausea, sexual dysfunction, and skin reactions. Additionally, caution should be applied if the patient is currently pregnant, breastfeeding, or has a renal implant.
Acamprosate on Pipelinepharma:
Acamprosate is currently available for wholesale order from our online B2B marketplace, consisting of a global network of trusted manufacturers, distributors, and suppliers. Currently, at the time of writing, there is one company with acamprosate on their pharmaceutical products list, situated in India. These companies are verified by the Pipelinepharma team according to strict quality control, ensuring a streamlined sourcing process with no time wasted on dead ends.
Price of acamprosate and how to buy:
As with other products on the online Pipelinepharma marketplace, the cost of individual sales of acamprosate cannot be divulged due to confidentiality between both B2B parties. Additionally, prices are rarely stationary with variations being negotiated online on a case by case basis, influenced by factors such as order size and location. However, manufacturers and wholesale sellers may have chosen to include the desired price for their listing along with any supplementary information. If so, this will be indicated on the product list, facilitating negotiation. An ‘Accept’ and ‘Negotiate’ button will be displayed if the desired price is provided, and a ‘Get offer’ button will be shown if there is no price listed.